Psychiatric disorders in Post-acute COVID-syndrome (PDPACS): Recommendations for health care professionals

Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes

“…Continuous psychoeducational support was provided to all patients, as recently recommended for the management of psychiatric disorders in post-COVID-19 syndrome ( Paez et al, 2022 ). The study protocol was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki (1964) and subsequent revisions and was approved by the local institutional review board.…”

Silexan for treatment of anxiety and depression in the context of COVID-19

“…According to the Global Burden of Disease Study from 2019, anxiety and depressive diseases remain among the top ten leading causes of burden worldwide ( Collaborators 2022 ). In 2020, when the coronavirus-19 disease (COVID-19) pandemic emerged, a globally increased prevalence of anxiety and depression and the related burden was consistently identified ( Paez, Nicolalde et al 2022 ). The phytopharmacotherapeutic agent Silexan represents a proprietary active substance manufactured for oral administration from Lavandula angustifolia that repeatedly showed favorable safety profile and anxiolytic efficacy in subthreshold and generalized anxiety disorder (GAD), and in mixed anxiety and depressive disorder (MADD).…”